Cheng-ho Jimmy Lin MD, PhD, MHS

Jimmy Lin, MD, PhD, MHS has been appointed as Chief Scientific Officer for Oncology. Dr. Jimmy Cheng-Ho Lin joins Natera coming from a long history as a pioneer in cancer genomics. Most recently, he led the clinical genomics program at the National Cancer Institute at the National Institutes of Health. Previously, at Johns Hopkins, Dr. Lin led the computational analysis of the first ever exome sequencing studies in cancer, including breast, colorectal, pancreatic, glioblastoma, medulloblastoma, and melanoma.

In addition, Dr. Lin is the Founder and President of Rare Genomics Institute, the world's first platform to enable any community to leverage cutting-edge biotechnology to advance understanding of any rare disease. Dr. Lin is a 2012 TED fellow and has spoken at many TED and TEDx events. He has numerous publications in Science, Nature, Cell, Nature Genetics, and Nature Biotechnology, and has been featured in multiple outlets including Forbes, Bloomberg Businessweek, Wall Street Journal, New York Times, Washington Post, the Huffington Post, and the Financial Times. Dr. Lin holds an MHS in Bioinformatics, a PhD in Cellular and Molecular Medicine, and an MD from Johns Hopkins University as well dual majors in Cognitive Science and Molecular Biophysics and Biochemistry from Yale University.